keyword
https://read.qxmd.com/read/38116484/invasive-fungal-infections-in-hematologic-malignancies-incidence-management-and-antifungal-therapy
#21
REVIEW
Fatemeh Shafiee, Rasool Soltani, Mohsen Meidani
The incidence of invasive fungal infections (IFIs) has increased in recent years as a result of increasing the incidence of hematologic malignancies (HMs). IFIs, as the opportunistic diseases, are the most important concern in these patients with a high mortality rate. These infections are one of the leading causes of morbidity and mortality in HM patients and an important factor in increasing the costs of patients' management because of the prolonged hospitalization and the inevitable need to use antifungal agents...
2023: Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences
https://read.qxmd.com/read/38113468/bendamustine-lymphodepletion-before-axicabtagene-ciloleucel-is-safe-and-associates-with-reduced-inflammatory-cytokines
#22
JOURNAL ARTICLE
Guido Ghilardi, Luca Paruzzo, Jakub Svoboda, Elise A Chong, Alexander A Shestov, Linhui Chen, Ivan J Cohen, Giulia Gabrielli, Sunita D Nasta, Patrizia Porazzi, Daniel J Landsburg, James N Gerson, Jordan Carter, Stefan K Barta, Rebecca Dawn Yelton, Raymone Pajarillo, Vrutti Patel, Griffin White, Hatcher Ballard, Elizabeth Weber, Ellen B Napier, Emeline R Chong, Joseph A Fraietta, Alfred Garfall, David L Porter, Michael C Milone, Roddy S O'Connor, Stephen J Schuster, Marco Ruella
Lymphodepletion (LD) is an integral component of chimeric antigen receptor T cell immunotherapies (CART). In this study, we compared the safety and efficacy of bendamustine (Benda) with standard fludarabine/cyclophosphamide (Flu/Cy) LD before CD19-directed, CD28-costimulated CART axicabtagene ciloleucel (axi-cel) in patients with large B-cell lymphomas (LBCL) and follicular lymphoma (FL). We analyzed 59 patients diagnosed with LBCL (48) and FL (11) consecutively treated with axi-cel at the University of Pennsylvania...
December 19, 2023: Blood Advances
https://read.qxmd.com/read/38110726/comparison-of-global-decolonization-efficacy-with-mupirocin-nasal-drop-and-chlorhexidine-mouthwash-in-acute-leukemia-patients-randomized-clinical-trial
#23
RANDOMIZED CONTROLLED TRIAL
Saba Ghaffary, Aref Javidnia, Samineh Beheshtirouy, Javid Sadeghi, Aliakbar Movassaghpour Akbari, Hamed Hamishehkar, Parvin Sarbakhsh, Zohreh Sanaat, Alireza Nikanfar, Ali Esfahani, Seyed Hadi Chavoshi, Babak Nejati, Mortaza Raeisi, Nasrin Gholami
PURPOSE: Neutropenic fever remains a major complication in acute leukemia. Decolonization is assumed as a promising intervention for eradicating causative agents of infection. METHODS: In this randomized clinical trial, 96 patients with acute leukemia were assigned randomly to mupirocin nasal drop 2% (n = 32), chlorhexidine mouthwash 0.2% (n = 33), and control group (n = 31). In control group, patients did not receive any medication for decolonization...
December 19, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/38102639/evaluating-the-cost-effectiveness-of-18-f-fdg-pet-ct-for-investigation-of-persistent-or-recurrent-neutropenic-fever-in-high-risk-haematology-patients
#24
JOURNAL ARTICLE
Michelle Tew, Abby P Douglas, Jeff Szer, Ashish Bajel, Simon J Harrison, Shio Yen Tio, Leon J Worth, Rodney J Hicks, David Ritchie, Monica A Slavin, Karin A Thursky, Kim Dalziel
BACKGROUND: A recent randomised trial demonstrated [18 F]fluorodeoxyglucose positron-emission tomography in combination with low-dose CT (FDG-PET/CT), compared to standard of care computed tomography (CT) imaging, positively impacted antimicrobial management and outcomes of acute leukaemia and haematopoietic stem cell transplant recipients with persistent and recurrent neutropenic fever. We conducted an economic evaluation from a healthcare perspective alongside the clinical trial. METHODS: Unit costs in Australian dollars were applied to all resources used (antimicrobials, diagnostic tests, ICU and hospital bed days)...
December 15, 2023: Cancer Imaging: the Official Publication of the International Cancer Imaging Society
https://read.qxmd.com/read/38088980/routine-infectious-disease-consultation-prior-to-an-allogeneic-hematopoietic-cell-transplant
#25
JOURNAL ARTICLE
Vera Portillo, Stavroula Masouridi-Levrat, Yves Chalandon, Maria Mappoura, Sarah Morin, Annalisa Marinosci, Federica Giannotti, Anne-Claire Mamez, Christian van Delden, Dionysios Neofytos
BACKGROUND: A transplant infectious disease (TID) assessment is essential to select recipients for an allogeneic hematopoietic cell transplant (HCT) and tailor prophylactic and empirical treatment recommendations. METHODS: We performed a retrospective single-center study to describe our model of care based on a routine TID consultation prior to an allogeneic HCT between 2018 and 2022 in 292 adult (≥18-year-old) consecutive patients. We describe the performance of a TID consultation, arbitrarily defined as major (HCT postponement, procedure, cytomegalovirus [CMV] recipient serology reinterpretation) and minor interventions...
December 2023: Open Forum Infectious Diseases
https://read.qxmd.com/read/38060973/prospective-external-validation-of-the-esbenshade-vanderbilt-models-accurately-predicts-bloodstream-infection-risk-in-febrile-non-neutropenic-children-with-cancer
#26
JOURNAL ARTICLE
Zhiguo Zhao, Pratik A Patel, Leonora Slatnick, Anna Sitthi-Amorn, Kevin J Bielamowicz, Farranaz A Nunez, Alexandria M Walsh, Jennifer Hess, Jenna Rossoff, Caitlin Elgarten, Regina Myers, Raya Saab, Maya Basbous, Meghan Mccormick, Catherine Aftandilian, Rebecca Richards, C Nathan Nessle, Alison C Tribble, Jessica K Sheth Bhutada, Scott L Coven, Daniel Runco, Jennifer Wilkes, Arun Gurunathan, Terri Guinipero, Jennifer A Belsky, Karen Lee, Victor Wong, Megha Malhotra, Amy Armstrong, Lauren P Jerkins, Shane J Cross, Lyndsay Fisher, Madison T Stein, Natalie L Wu, Troy Yi, Etan Orgel, Gabrielle M Haeusler, Joshua Wolf, Jenna M Demedis, Tamara P Miller, Adam J Esbenshade
PURPOSE: The optimal management of fever without severe neutropenia (absolute neutrophil count [ANC] ≥500/µL) in pediatric patients with cancer is undefined. The previously proposed Esbenshade Vanderbilt (EsVan) models accurately predict bacterial bloodstream infections (BSIs) in this population and provide risk stratification to aid management, but have lacked prospective external validation. MATERIALS AND METHODS: Episodes of fever with a central venous catheter and ANC ≥500/µL occurring in pediatric patients with cancer were prospectively collected from 18 academic medical centers...
March 1, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38026107/an-uncommon-culprit-of-neutropenic-fever-a-case-of-sweet-syndrome-following-induction-therapy-for-acute-myeloid-leukemia
#27
Ahmed Alderazi, Alec B Rezigh
Sweet syndrome (SS) is a rare inflammatory disorder characterized by the rapid onset of a characteristically tender rash, fever, and other systemic symptoms. These manifestations are often mistaken for an infection that is not responding to antimicrobials, especially in immunocompromised hosts. We present the case of a 44-year-old woman who developed SS following induction chemotherapy for newly diagnosed acute myeloid leukemia (AML). She exhibited a painful rash on the anterior chest, which spread centrifugally, along with neutropenic fever unresponsive to broad-spectrum antimicrobials...
2023: Archive of clinical cases
https://read.qxmd.com/read/38021097/implementation-of-a-protocol-for-management-of-febrile-neutropenia-in-the-emergency-department-at-veteran-health-indiana
#28
JOURNAL ARTICLE
Lori Melikian, Susan Bullington, Brent Harris, Cole Smith, Justin Roberts, Chad Naville-Cook, Brooke Crawford
BACKGROUND: Febrile neutropenia (FN) is a life-threatening oncologic emergency requiring timely evaluation and treatment. Unrecognized fever and infection can progress quickly and have been shown to increase morbidity and mortality in patients with malignancy. It is critical to identify patients with neutropenic fever on presentation to the emergency department (ED) and to initiate treatment immediately. OBSERVATIONS: This quality improvement initiative sought to optimize ED care of patients presenting with FN...
August 2023: Federal Practitioner
https://read.qxmd.com/read/37947888/low-utilization-of-vancomycin-in-febrile-neutropenia-real-world-evidence-from-4-brazilian-centers
#29
JOURNAL ARTICLE
Jessica Fernandes Ramos, André Domingues Pereira, Maria Cristina Nunez Seiwald, Larissa Simão Gandolpho, Vinicius Campos Molla, Mariana Guaraná, Simone A Nouér, Marcio Nucci, Celso Arrais Rodrigues
PURPOSE: The prompt initiation of a betalactam antibiotic in febrile neutropenic patients is considered standard of care, while the empiric use of vancomycin is recommended by guidelines in specific situations, with a low level of evidence. The objective of this study was to assess the utilization of vancomycin in the management of febrile neutropenia within four Brazilian medical centers that implemented more stringent criteria for its administration. METHODS: A comprehensive retrospective analysis was performed encompassing all instances of febrile neutropenia observed during the period from 2013 to 2019...
November 10, 2023: Supportive Care in Cancer
https://read.qxmd.com/read/37932689/comparison-of-3-and-4-cycles-of-neoadjuvant-gemcitabine-and-cisplatin-for-muscle-invasive-bladder-cancer-a-systematic-review-and-meta-analysis
#30
JOURNAL ARTICLE
Lanpeng Lu, Chaohu Chen, Hui Cheng, Hui Ding, Junqiang Tian, Hanzhang Wang, Zhiping Wang
BACKGROUND: In muscle-invasive bladder cancer (MIBC), neoadjuvant chemotherapy (NAC) combined with radical cystectomy (RC) is critical in reducing disease recurrence, with GC (gemcitabine and cisplatin) being one of the most commonly used NACs. Different GC schedules have been used, but the best neoadjuvant regimen is still unknown. The clinical outcomes of 3 and 4 cycles of neoadjuvant GC are compared in this systematic review and meta-analysis to determine which is best for patients with MIBC...
November 6, 2023: BMC Cancer
https://read.qxmd.com/read/37919603/markers-of-intestinal-mucositis-to-predict-blood-stream-infections-at-the-onset-of-fever-during-treatment-for-childhood-acute-leukemia
#31
JOURNAL ARTICLE
Sarah Weischendorff, Mathias Rathe, Malene Johanne Petersen, Allan Weimann, Christian Enevold, Claus H Nielsen, Bodil Als-Nielsen, Ulrikka Nygaard, Claus Moser, Klaus Müller
Despite chemotherapy-induced intestinal mucositis being a main risk factor for blood stream infections (BSIs), no studies have investigated mucositis severity to predict BSI at fever onset during acute leukemia treatment. This study prospectively evaluated intestinal mucositis severity in 85 children with acute leukemia, representing 242 febrile episodes (122 with concurrent neutropenia) by measuring plasma levels of citrulline (reflecting enterocyte loss), regenerating islet-derived-protein 3α (REG3α, an intestinal antimicrobial peptide) and CCL20 (a mucosal immune regulatory chemokine) along with the general neutrophil chemo-attractants CXCL1 and CXCL8 at fever onset...
November 2, 2023: Leukemia
https://read.qxmd.com/read/37915650/neutropenic-enterocolitis-in-aplastic-anemia-a-case-report-from-nepal
#32
JOURNAL ARTICLE
Jagdish Sharma, Anshumala Adhikari, Ashik Basnet, Dharana Gelal, Shivani Singh, Aavash Mishra
INTRODUCTION AND IMPORTANCE: Neutropenic enterocolitis (NE) is a life-threatening necrotizing enterocolitis, particularly in neutropenic patients. CASE PRESENTATION: We are presenting a case of a 22-year-old male who presented chief complaints of abdominal pain, reddish black stool, abdominal distention, and low-grade fever with laboratory and bone marrow findings suggestive of aplastic anemia. Computed tomography scan of the abdomen and pelvis with contrast was used to establish the diagnosis of necrotizing enterocolitis...
November 2023: Annals of Medicine and Surgery
https://read.qxmd.com/read/37900520/the-characteristics-and-follow-up-of-sars-cov-2-infection-in-pediatric-oncology-patients
#33
JOURNAL ARTICLE
Raghad Alkharouby, Noura Aljehani, Nasser Alsubaie, Anas Alqarni, Mohammed Hariri, Naglla Elimam, Baraa AlhajHussein, Aeshah A AlAzmi
Introduction Clinical data about the first and second most prominent waves of SARS-CoV-2 among pediatric cancer patients were inconsistent. This study aims to retrospectively report the clinical characteristics and outcomes of SARS-CoV-2 infection in pediatric oncology patients. Methods This is an observational, retrospective study conducted in a tertiary care oncology center from March 2020 to May 2022. We reviewed the prevalence, severity of symptoms, and duration of positivity in relation to blood count laboratory data and mortality with a follow-up of 30 days post-infection for SARS-CoV-2...
September 2023: Curēus
https://read.qxmd.com/read/37879723/pharmaceutical-industry-payments-and-delivery-of-non-recommended-and-low-value-cancer-drugs-population-based-cohort-study
#34
JOURNAL ARTICLE
Aaron P Mitchell, Stacie B Dusetzina, Akriti Mishra Meza, Niti U Trivedi, Peter B Bach, Aaron N Winn
OBJECTIVE: To estimate the association between oncologists' receipt of payments from the pharmaceutical industry and delivery of non-recommended or low value interventions among their patients. DESIGN: Cohort study. SETTING: Fee-for-service Medicare claims. PARTICIPANTS: Medicare beneficiaries with a diagnosis of incident cancer (new occurrence of a cancer diagnosis code in proximity to claims for cancer treatment, and no such diagnosis codes during a ≥1 year washout period) during 2014-19, who met additional requirements identifying them as at risk for one of four non-recommended or low value interventions: denosumab for castration sensitive prostate cancer, granulocyte colony stimulating factors (GCSF) for patients at low risk for neutropenic fever, nab-paclitaxel for cancers with no evidence of superiority over paclitaxel, and a branded drug in settings where a generic or biosimilar version was available...
October 25, 2023: BMJ: British Medical Journal
https://read.qxmd.com/read/37878097/-duration-of-antibiotic-therapy-in-febrile-neutropenia
#35
JOURNAL ARTICLE
Jasmine Mohamad, Olivier Grosgurin, Antonio Leidi, Dionysios Neofytos, Christophe Marti
Febrile neutropenia is a frequent complication of cancer treatment and is associated with an increased risk of morbidity and mortality. However, standardization in the management of neutropenic fever has led to a reduction in its complications. The duration and type of antibiotic therapy differ according to guidelines, particularly in cases of febrile neutropenia of unknown origin. Continuation of antibiotic treatment until resolution of neutropenia has historically been recommended but exposes patients to prolonged periods of broad-spectrum antibiotic therapy...
October 25, 2023: Revue Médicale Suisse
https://read.qxmd.com/read/37872935/very-severe-aplastic-anemia-in-a-26-year-old-male-implications-for-prognosis-and-treatment-options
#36
Ahmed Alobaidi, Ahmed Albadry, Anne Murray
Aplastic anemia (AA) is a hematopoietic stem cell (HSC) disorder characterized by the loss of HSCs, bone marrow failure, and peripheral pancytopenia. AA is classified as very severe (VSAA), severe (SAA), or non-severe (NSAA) based on the severity criteria. This classification system has implications for the prognosis and treatment options offered to patients. The prognosis of AA has improved over the past several decades with the advancements in supportive care, HSC transplant (HCT), and immunosuppressive therapy (IST)...
September 2023: Curēus
https://read.qxmd.com/read/37868579/nivolumab-induced-isolated-neutropenia
#37
Aimal Waqas, Javariya Zaffar, Ahmad Jalil, Shayan Butt
Immune checkpoint inhibitors (ICIs) have been discovered to be associated with autoimmune toxicities that may present as dermatologic, gastrointestinal, hepatic, pulmonary, endocrine, and rarely hematologic reactions. Recent studies have also discovered hematological adverse effects as a result of ICI use of which isolated neutropenia is the gravest and the rarest manifestation. Asymptomatic neutropenia cannot be ignored, and close monitoring is, at least, warranted. Severe neutropenia with neutropenic fever needs hospital admission and prompt treatment to avoid further morbidity and/or mortality...
September 2023: Curēus
https://read.qxmd.com/read/37845401/the-vanishing-nasal-septum-sign-a-case-of-severe-fungal-sinusitis
#38
JOURNAL ARTICLE
Albert Tine, Sarina Masso Maldonado, Francis J Cloran
Acute invasive fungal sinusitis (AIFS) is a fungal infection of the nasal cavity and paranasal sinuses with associated invasion of adjacent vessels and soft/hard tissues. It usually occurs in immunocompromised patients and may follow a rapid course of less than four weeks with high mortality rate. We report a 39-year-old male with relapse of acute myelogenous leukemia (AML) who was under evaluation for neutropenic fever. On his sinus CT, there was loss of calcification of his nasal septum when compared to a prior head CT, a sign indicative of an aggressive infectious process...
October 17, 2023: Emergency Radiology
https://read.qxmd.com/read/37843249/biomarker-driven-phase-2-umbrella-trial-clinical-efficacy-of-olaparib-monotherapy-and-combination-with-ceralasertib-azd6738-in-small-cell-lung-cancer
#39
JOURNAL ARTICLE
Sehhoon Park, Yu Jung Kim, Young Joo Min, Peter G S Mortimer, Hee-Jung Kim, Simon A Smith, Emma Dean, Hyun Ae Jung, Jong-Mu Sun, Woong-Yang Park, Jin Seok Ahn, Myung-Ju Ahn, Se-Hoon Lee, Keunchil Park
BACKGROUND: Based on a high incidence of genomic alteration in the cell cycle and DNA damage and response (DDR)-related pathways in small cell lung cancer (SCLC), the clinical efficacy of the DDR-targeting agent olaparib (PARP inhibitor) as monotherapy and in combination with ceralasertib (ATR inhibitor) in relapsed or refractory SCLC was evaluated. METHODS: As part of a phase 2 biomarker driven umbrella study, patients with SCLC and predefined DDR gene alterations who failed to benefit from prior platinum-based regimens were allocated to the olaparib monotherapy arm and nonbiomarker-selected patients were allocated to the olaparib and ceralasertib combination arm...
February 15, 2024: Cancer
https://read.qxmd.com/read/37835477/prospective-comparative-study-of-etoposide-plus-g-csf-versus-g-csf-alone-followed-by-risk-adapted-plerixafor-for-peripheral-blood-stem-cell-mobilization-in-patients-with-newly-diagnosed-multiple-myeloma-catholic-research-network-for-multiple-myeloma-study-caremm
#40
JOURNAL ARTICLE
Sung-Soo Park, Seung-Hwan Shin, Jung-Yeon Lee, Young-Woo Jeon, Seung-Ah Yhang, Chang-Ki Min
To explore the optimal mobilization for multiple myeloma (MM) patients, we conducted a prospective trial comparing single-dose etoposide (375 mg/m2 for one day) plus G-CSF versus G-CSF alone, followed by risk-adapted plerixafor. After randomization, 27 patients in the etoposide group and 29 patients in the G-CSF alone group received mobilizations. Six (22.2%) patients in the etoposide group and 15 (51.7%) patients in the G-CSF alone group received plerixafor based on a peripheral blood CD34+ cell count of < 15/mm3 ( p = 0...
September 28, 2023: Cancers
keyword
keyword
45469
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.